{"page":{"totalFilteredElements":344},"studies":[{"active":true,"description":"<u>Na</u>tional acute <u>p</u>r<u>o</u>myelocytic <u>le</u>ukemia (APL) observational study NAPOLEON&#8208;Register der Deutschen AML Intergroup<br />","eudractNumber":null,"id":1351,"indications":[{"id":"leu","name":"Leukämien"},{"id":"leu2","name":"Akute myeloische Leukämie (AML)"}],"mutations":[{"name":"Fusion Transcript of PML/RARa","id":"mt_269"},{"name":"Others","id":"mt_8"},{"name":"Translokation","id":"mt_244"},{"name":"t(15;17)","id":"mt_179"}],"nctNumber":"NCT02192619","phase":null,"recruitmentStart":"2014-07-21T09:49:50+02:00","shortTitle":"NAPOLEON-Register","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"Prospektive nicht-interventionelle Studie (NIS) zur Untersuchung der Wirksamkeit von Tremilimumab &amp; Durvalumab + platinbasierter Chemotherapie (TDC) in Patient:innen mit metastasiertem nicht-plattenepithelialem NSCLC und Risikomutationen.","eudractNumber":null,"id":11012,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun2","name":"Nicht-kleinzelliges Bronchialkarzinom (NSCLC)"}],"mutations":[{"name":"KEAP1 (Kelch-like ECH-associated protein 1)","id":"mt_251"},{"name":"ras-Gen","id":"mt_28"},{"name":"KRAS","id":"mt_7"},{"name":"STK11 (Serine/threonine kinase 11)","id":"mt_253"},{"name":"TP53","id":"mt_24"}],"nctNumber":"NCT06494540","phase":{"id":"ph_11","name":"Phase IV"},"recruitmentStart":"2025-02-04T10:40:14+01:00","shortTitle":"NAUTIC","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Prospective multicenter registry for neonates, infants, children, adolescents, and adults with neuroblastic tumours.<br />","eudractNumber":null,"id":3381,"indications":[{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped3","name":"Hirntumore (Tumore des zentralen Nervensystems)"},{"id":"ped4","name":"Weitere solide Tumore"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":"2017-01-01T09:38:52+01:00","shortTitle":"NB Registry 2016","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"<p class=\"MsoNormal\" align=\"center\" style=\"text-align:left;\">Pr&#228;diktion des\nAnsprechens auf Hypertherme Intraperitoneale Chemotherapie in gastrointestinalen Krebserkrankungen (Hi-STEP1)</p><p class=\"MsoNormal\" align=\"center\" style=\"text-align:left;\">DRKS00028836</p>","eudractNumber":null,"id":10899,"indications":[{"id":"gio","name":"Bösartige Erkrankungen des oberen Verdauungstraktes (Oesophagus, Magen, gastrooesophagealer Übergang)"},{"id":"gio2","name":"Karzinom des gastrooesophagealen Übergangs"},{"id":"gio3","name":"Magenkarzinom"},{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2025-07-06T09:06:56+02:00","shortTitle":"NCT Hi-STEP1","therapeutical":false,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Comprehensive assessment of clinical features and biomarkers to \nidentify patients with advanced or metastatic breast cancer for \nmarker driven trials in humans (CATCH).","eudractNumber":null,"id":10013,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"}],"mutations":[],"nctNumber":"NCT05652569","phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2024-08-08T11:30:37+02:00","shortTitle":"NCT-Studie: CATCH","therapeutical":true,"therapyLines":[]},{"active":true,"description":"Comprehensive assessment of clinical features, genomics and further molecular markers to identify patients with <u>early breast cancer</u> for enrolment on marker driven trials (COGNITION)","eudractNumber":null,"id":9308,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"}],"mutations":[],"nctNumber":"NCT05906407","phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2025-01-08T11:29:31+01:00","shortTitle":"NCT-Studie: COGNITION","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"&#160;COGNITION-GUIDE&#160;Genomics guided targeted post-neoadjuvant therapy in patients with&#160;early breast cancer- a multicenter, open-label, umbrella phase -II study<div>2020-002606-22 ( EudraCT Number )</div>","eudractNumber":"2024-514022-23-00","id":11293,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"}],"mutations":[],"nctNumber":"NCT05332561","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2025-09-04T09:29:00+02:00","shortTitle":"NCT-Studie: COGNITION-Guide","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"A Phase I clinical trial to assess safety and tolerability of autologous ROR1 CAR-T cells in ROR1+ tumors","eudractNumber":"2024-512019-36","id":10837,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn3","name":"Eierstockkrebs (Ovarialkarzinom)"},{"id":"nen","name":"Bösartige Tumoren der Nebenniere"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[{"name":"ROR 1","id":"mt_288"}],"nctNumber":null,"phase":{"id":"ph_3","name":"Phase I"},"recruitmentStart":"2025-04-09T13:41:47+02:00","shortTitle":"NCT-Studie: LION 1","therapeutical":true,"therapyLines":[{"id":"tl_3","name":"Drittlinie"},{"id":"tl_10","name":"First in Human (FIH) Studie"}]},{"active":true,"description":"<p class=\"MsoNormal\" style=\"line-height:normal;\">National Center for Tumor Diseases / German Cancer Consortium (NCT/DKTK) Molecularly Aided Stratification for Tumor Eradication Research (MASTER)</p><p class=\"MsoNormal\" style=\"line-height:normal;\"><b>NCT MASTER Program</b></p>","eudractNumber":null,"id":4421,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn3","name":"Eierstockkrebs (Ovarialkarzinom)"},{"id":"gio","name":"Bösartige Erkrankungen des oberen Verdauungstraktes (Oesophagus, Magen, gastrooesophagealer Übergang)"},{"id":"gio3","name":"Magenkarzinom"},{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"},{"id":"nen","name":"Bösartige Tumoren der Nebenniere"},{"id":"sar","name":"Sarkome"},{"id":"sar1","name":"Knochensarkome (Ewing-Sarkom, Osteosarkom etc.)"},{"id":"sar2","name":"Weichteilsarkome (Liposarkom, Leiomyosarkom, etc.)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2018-01-01T10:53:33+01:00","shortTitle":"NCT-Studie: MASTER Programm","therapeutical":true,"therapyLines":[]},{"active":true,"description":"Prospektive Beobachtungsstudie mit Erstellung einer Biodatenbank zur Untersuchung potentieller Biomarker f&#252;r Risikostratifizierung, Therapiesteuerung und Vertr&#228;glichkeit in Patient*innen mit neuroendokrinen Neoplasien (NENReg)","eudractNumber":null,"id":11499,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn3","name":"Eierstockkrebs (Ovarialkarzinom)"},{"id":"pro","name":"Prostatakrebs"},{"id":"gio","name":"Bösartige Erkrankungen des oberen Verdauungstraktes (Oesophagus, Magen, gastrooesophagealer Übergang)"},{"id":"gio1","name":"Karzinom der Speiseröhre (Oesophaguskarzinom, inkl. gastrooesophagealer Übergang)"},{"id":"gio2","name":"Karzinom des gastrooesophagealen Übergangs"},{"id":"gio3","name":"Magenkarzinom"},{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"giu2","name":"Leber (Hepatozelluläres Karzinom, HCC) / Gallenblase-/wege (Cholangiozelluläres Karzinom, CCC)"},{"id":"giu3","name":"Bauchspeicheldrüsenkrebs (Pankreaskarzinom)"},{"id":"hno","name":"Kopf/Hals Tumoren"},{"id":"hno1","name":"Mundhöhlenkarzinom, Rachenkarzinom, inkl. Mundboden- und Zungengrundkarzinom"},{"id":"hno2","name":"Kehlkopfkrebs (Larynxkarzinom)"},{"id":"nen","name":"Bösartige Tumoren der Nebenniere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2025-11-01T09:14:44+01:00","shortTitle":"NENReg","therapeutical":false,"therapyLines":[]}]}